Better treatment options for children with renal tumours
The “SIOP Randomet 2017” trial is an international therapy optimisation trial for the treatment of children and adolescents with an advanced malignant renal tumour. Although the disease is rare, it has a major impact on patients and their families. The Swiss Paediatric Oncology Group (SPOG) gives children and young people in Switzerland who suffer from a renal tumour access to the results of this new trial.
“Thanks to fantastic therapy trials such as SIOP Randomet 2017, we can not only cure more children with cancer today, but also optimise the therapy – also with regard to possible side effects and late effects,” explains Dr. Sabine Kroiss (MD), trial lead and senior physician at the University Children’s Hospital Zurich.
The current standard therapy for young patients with a renal tumour with metastases consists of short, but intensive chemotherapy, a subsequent operation to remove the tumour followed by a further, longer course of chemotherapy after the operation. Some of those affected also need radiotherapy.
A particular challenge is the severe, potentially life-threatening side effects that chemotherapy before surgery can cause in a worst case scenario. This trial is looking into whether a comparative therapy, with less frequent and less severe side effects, can control the disease as well as the current standard therapy.
You can find out more information on “SIOP Randomet 2017” here.